Clinical trial
A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Major Depressive Disorder (MDD)
NCT06423781 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Major Depressive Disorder (MDD)
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 1, 2024
- Completion date
- March 18, 2026
- Enrollment
- 233 (actual)
- Sites
- 66
Conditions
As the registry lists them; a condition with its own page is linked.